Back

Alternative Anastrozole Target CYP4V2 Impairs Neurons in Preclinical Models of Inherited Tauopathy

Pedicone, C.; Weitzman, S.; Orrick, J.; Pugh, D.; Goate, A. M.; Cagan, R.; Bowles, K.; Sonoshita, M.

2025-11-29 neuroscience
10.1101/2025.11.29.689498 bioRxiv
Show abstract

Tauopathies, including Alzheimer disease, are neurodegenerative diseases characterized by the pathological aggregation of the microtubule-associated protein Tau (MAPT). This study explores the neuroprotective properties of anastrozole, a clinical Aromatase inhibitor, in both a Drosophila tauopathy model expressing human MAPTR406W and isogenic pairs of human induced pluripotent stem cell-derived cortical neurons expressing MAPT mutations. The Aromatase inhibitor anastrozole, initially identified in a Drosophila MAPTR406W drug screen, reduced oxidative stress and Tau phosphorylation in cultured cortical neurons. Its protective effects were not mediated by Aromatase activity or cholesterol metabolism: screening in Drosophila identified CYP4V2 as a potential off-target. Knockdown of CYP4V2 in MAPTR406W neurons recapitulated protection against oxidative stress-induced cell death. These findings position anastrozole and its offtarget CYP4V2 as novel therapeutic avenues for primary tauopathies and potentially Alzheimers disease and related dementias by reducing Tau phosphorylation and susceptibility to oxidative stress.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 15%
11.9%
Similar papers in this journal
2
Molecular Psychiatry
○ 282 papers in training set
Top 0.5%
11.0%
Similar papers in this journal
3
Alzheimer's & Dementia
177 papers in training set
Top 0.8%
6.7%
4
Cell Reports
○ 1498 papers in training set
Top 6%
5.6%
Similar papers in this journal
5
eLife
● 5828 papers in training set
Top 24%
5.2%
Similar papers in this journal
6
Molecular Neurodegeneration
○ 55 papers in training set
Top 0.4%
4.9%
7
Scientific Reports
○ 3612 papers in training set
Top 28%
3.5%
8
Neurobiology of Disease
○ 148 papers in training set
Top 1%
3.2%
50% of probability mass above
9
Science Advances
● 1243 papers in training set
Top 11%
3.2%
10
Communications Biology
○ 993 papers in training set
Top 9%
2.4%
11
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 21%
2.4%
12
iScience
○ 1154 papers in training set
Top 13%
2.1%
13
Neuron
○ 337 papers in training set
Top 3%
2.1%
14
Cell Death & Disease
147 papers in training set
Top 1%
2.1%
15
npj Parkinson's Disease
○ 105 papers in training set
Top 0.8%
1.9%
16
Translational Psychiatry
○ 260 papers in training set
Top 3%
1.5%
17
Acta Neuropathologica
○ 58 papers in training set
Top 0.9%
1.4%
18
Aging Cell
○ 165 papers in training set
Top 2%
1.3%
19
EMBO Molecular Medicine
○ 95 papers in training set
Top 1%
1.1%
20
Stem Cell Reports
○ 130 papers in training set
Top 1%
1.1%
21
Journal of Biological Chemistry
○ 690 papers in training set
Top 7%
1.1%
22
Nature Metabolism
○ 69 papers in training set
Top 1%
1.1%
23
Life Science Alliance
● 285 papers in training set
Top 6%
1.1%
24
The Journal of Neuroscience
● 1025 papers in training set
Top 9%
1.0%
25
The EMBO Journal
○ 309 papers in training set
Top 5%
1.0%
26
PLOS Biology
● 486 papers in training set
Top 11%
0.8%
27
Cell Chemical Biology
○ 94 papers in training set
Top 2%
0.6%
28
Acta Neuropathologica Communications
○ 89 papers in training set
Top 2%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.